Thymosin alpha-1 (Tα1, or thymalfasin) is a tiny peptide hormone - a small immune-signaling protein - made of exactly 28 amino acids. First isolated in 1977, it is the most clinically advanced immune peptide globally. While often discussed in alternative medicine, it is crucial to note that it is a potent prescription drug in specific disease contexts, not a general wellness supplement.

What is Thymosin alpha-1?

Thymosin alpha-1 (Tα1, or thymalfasin) is a naturally occurring 28-amino acid immunomodulatory peptide hormone first isolated from the thymus gland in 1977. It is utilized clinically as a prescription drug primarily to treat viral hepatitis B and C (HBV and HCV) and as a supportive therapy in oncology, though it remains entirely unsuitable and unproven for general health optimization or anti-aging.

Technically, Tα1 is the active first section (the N-terminal region) of a larger precursor protein called prothymosin. It is tiny - roughly 3,108 daltons (Da, the unit chemists use to weigh such small protein building blocks), which is why doses are measured in milligrams. It is produced synthetically today to ensure purity and consistency. While it is a prescription drug approved in over 35 countries for severe illnesses, there are zero large-scale clinical trials supporting its popular use for "immune boosting" or "anti-aging" in healthy individuals.

Substance	Class / Mechanism	Primary Use & Effect Size	Regulatory Status
Thymosin alpha-1 (Tα1)	Immunomodulator (TLR 3/4/9 agonist)	HBV/HCV, Oncology support; established clinical efficacy	Approved in 35+ countries (Not US/EU)
Thymosin beta-4 (TB-500)	Actin-binding peptide	Tissue repair, wound healing; mostly animal data	Unapproved drug (US/EU)
Pegylated Interferon alpha-2a	Cytokine / Immune stimulant	Historical standard HBV/HCV therapy (now largely displaced by direct-acting antivirals in HCV)	Fully FDA/EMA approved

How does Thymosin alpha-1 work?

Tα1 is a small immune-signaling protein that boosts weak immune defenses while calming excessive ones. It modulates the immune system on multiple levels (pleiotropically). It does so by binding to three specific docking sites - Toll-like receptors 3, 4, and 9 (TLR3/4/9) - on dendritic cells (sentinel cells that alert the immune system by presenting threats) and on T lymphocytes (the actual fighter cells). This activates two key cellular switches, the IRF3 and NF-κB signaling pathways, which in turn trigger the release of immune messenger proteins called cytokines.

Through these pathways, Tα1 actively supports the maturation of young T-cells and shifts the balance toward a more effective Th1 cellular immune response. It significantly enhances the activity of natural killer (NK) cells and macrophages. In oncology, this dual action not only stimulates the immune system but also exerts a direct anti-proliferative effect, triggering apoptosis (programmed cell death) in leukemia, melanoma, lung, and breast cancer cell lines observed in vitro.

How effective is Thymosin alpha-1?

Thymosin alpha-1 demonstrates established clinical efficacy for approved indications like chronic hepatitis B and specific oncology applications, supported by robust trials. However, comprehensive evidence regarding its use in severe sepsis remains mixed, with the massive TESTS trial missing its primary endpoint, and there is absolutely no clinical validation for popular biohacking or anti-aging applications in healthy individuals.

A 2024 narrative review (an expert-written summary without new statistical pooling) compiled data from over 11,000 patients across more than 30 trials, confirming its utility in viral hepatitis and as an immune adjuvant in cancer therapy. For severe sepsis, a 2024 meta-analysis (a pooled statistical re-analysis of multiple trials) showed a trend toward mortality reduction, though the large phase III TESTS randomized controlled trial (RCT, the gold-standard study design; N=1,106 patients) ultimately missed its primary endpoint (the pre-specified main goal of the study) in the overall cohort (i.e. when analyzing all participants together). Any claims of benefit for general wellness, fatigue, or "anti-aging" lack scientific backing.

Dosage: what the studies show - and the protocol

Standard clinical research protocols for Thymosin alpha-1 typically dictate a subcutaneous injection of 1.6 mg administered twice a week over a sustained duration of 6 to 12 months, depending on the specific disease. These carefully titrated regimens are designed to gradually modulate the immune system, highlighting why casual or unsupervised self-experimentation deviates significantly from studied safety parameters.

Dosages are highly specific to the condition being treated. For example, HBV treatment requires long-term application to shift immune responses, while sepsis trials utilize short-term, intensive dosing. The 1.6 mg dose is standard for Zadaxin, but individual patient factors heavily influence the exact duration. This data reflects published clinical protocols for informational purposes and is not a medical recommendation.

Condition / Phase	Studied Dosage	Target & Clinical Note
Chronic Hepatitis B (HBV)	1.6 mg subcutaneously, twice weekly	Duration: 6 to 12 months. Goal: Long-term immune stimulation to clear the virus.
Oncology Support	1.6 mg subcutaneously, twice weekly	Given alongside chemotherapy or post-vaccination to enhance immune recovery.
Sepsis (Intensive Care)	1.6 mg subcutaneously, daily	Short-term intensive use (e.g., TESTS trial, 2024). Missed primary mortality endpoint but showed safety.

Mixing & dose calculation

Because Thymosin alpha-1 is a delicate peptide requiring subcutaneous administration, precise reconstitution and dose calculation are strictly necessary to maintain its stability and avoid hazardous contamination. Proper handling necessitates the use of medical-grade bacteriostatic water (sterile water with a preservative that inhibits bacterial growth) to dissolve the lyophilized powder and the employment of accurate insulin syringes to draw the exact volume required for clinical protocols.

Thymosin alpha-1 must be stored as a lyophilized (freeze-dried) powder in a refrigerator to prevent degradation. When reconstituted with bacteriostatic water, it must remain refrigerated and used within a specific timeframe to maintain sterility. Calculating the exact dose (e.g., drawing 1.6 mg from a standard 5 mg vial) requires precise mathematical calculation and strict aseptic technique (sterile, germ-free handling) to prevent dangerous bacterial infections at the injection site.

Side effects and common mistakes

While Thymosin alpha-1 is often marketed as having minimal side effects, documented adverse events range from mild injection site redness to severe hepatic and thyroid dysfunction, including rare fatal outcomes in transplant patients. This discrepancy underscores the critical need for medical supervision, as improper application or ignoring underlying autoimmune conditions poses a substantial risk of severe harm.

Commercial marketing frequently claims Tα1 has "essentially no side effects," but clinical trial reports and the FDA adverse event database (FAERS) tell a different story. These sources document severe risks in vulnerable populations, including fatal graft failure in hematopoietic stem cell transplant (HSCT) recipients, liver enzyme (ALT) flares in HBV patients, and thyroid abnormalities (TSH) in HCV patients. Severe autoimmune hemolysis (and in isolated cases, fatal immune-mediated hemolytic anemia) as well as breast tenderness have also been reported. It is contraindicated for individuals with active autoimmune diseases without strict medical oversight.

Using it for "anti-aging" or general wellness: There is zero clinical evidence supporting Tα1 use in healthy individuals; it exposes users to severe risks without proven benefits.
Ignoring autoimmune conditions: Because Tα1 powerfully stimulates the immune system, taking it with an undiagnosed or active autoimmune disease can dangerously exacerbate the condition.
Poor aseptic technique: Reconstituting peptide vials without proper sterilization or using non-medical-grade water can lead to life-threatening bacterial infections.
Buying from unregulated "peptide shops": Without verified pharmaceutical-grade purity, users risk introducing endotoxins (toxic fragments released by bacteria that can trigger severe immune reactions) and dangerous contaminants directly into their tissue, triggering severe immune reactions.

Approval and legal status

Thymosin alpha-1 is an approved prescription pharmaceutical in over 35 countries across Asia and South America for viral hepatitis and oncology support. However, it lacks approval by the United States FDA and has no centralized marketing authorization from the European Medicines Agency (EMA), making its legal acquisition and use in Europe and the USA highly restricted.

In the United States, the FDA Pharmacy Compounding Advisory Committee (PCAC) recommended in December 2024 against placing Tα1 on the 503A Bulks List, further restricting its legal compounding. In Germany and the broader EU, there is no regular market approval. Acquisition by residents usually occurs legally only via international pharmacies through specialized medical import channels, whereas purchasing it openly from local or online "peptide vendors" operates in a legal grey area or violates drug manufacturing laws. It is strictly not an over-the-counter dietary supplement.

Evidence at a glance

Research status

Thymosin Alpha-1 (Tα1) is approved in over 35 countries for hepatitis B and C, but is not FDA-approved in the United States [1, 4, 13]. The evidence base includes preclinical data (in vitro and in vivo) and human clinical evidence, such as a phase 3 trial and multiple meta-analyses [5, 6, 7, 12]. Mechanistically, Tα1 acts through Toll-like receptors (TLR3/4/9) in dendritic cells [5, 11]. In vitro studies show anti-proliferative effects on cancer cells [6], while in vivo animal studies report reduced metastases and carcinogenesis [6]. Human clinical development spans sepsis, COVID-19, hepatitis, cancer, and autoimmune diseases [2, 7, 12, 24]. However, the evidence relies heavily on systematic reviews and meta-analyses rather than uniformly high-quality, large-scale primary RCT data, though a recent phase 3 trial for sepsis is noted [1, 7, 12, 14, 15, 17, 19, 22].

Human evidence

For sepsis, multiple systematic reviews and meta-analyses of RCTs indicate that Tα1 may decrease 28-day mortality, and a phase 3 trial (TESTS) was published in 2025 [7, 12, 15, 19, 22]. For COVID-19, a meta-analysis of 8 studies suggests reduced mortality in moderate to critical patients, though further RCTs are needed [14, 16]. For Severe Acute Pancreatitis (SAP), a meta-analysis of 5 RCTs (706 patients) found increased CD4+ cells, improved CD4+/CD8+ ratio, and reduced CRP levels with lower doses [17]. For hepatitis B, an FDA review notes that monotherapy yielded mixed results across 5 studies, and modern antivirals have superseded it [3]. Reviews also summarize its clinical development as an immune adjuvant for non-small cell lung cancer, melanoma, and autoimmune diseases [2, 24].

Dosages in studies & practice

According to literature, Tα1 is usually administered subcutaneously twice a week, with standard single dosages ranging from 0.8 to 6.4 mg, and multiple doses ranging from 1.6 to 16 mg for five to seven days [1]. Other sources cite a typical dose of 1.6 mg via subcutaneous injection, twice weekly [21], which aligns with an FDA-cited protocol of up to 1.6 mg administered twice a week for up to 12 months for hepatitis B monotherapy [3]. In animal models, doses have included 0.01-10 μg for 7 days in mice, 10 μg in rats, and 0.4 mg/kg over 8 months in mice [6].

Risks & side effects

Tα1 has demonstrated a very favorable toxicity profile in over 3,000 treated individuals, including those with hepatocellular carcinoma, non-small-cell lung cancer, melanoma, and hepatitis B and C [8]. It is well-tolerated even in patients with decompensated liver disease, renal disease requiring hemodialysis, and primary immunodeficient individuals [8]. The most commonly reported adverse events are injection-site reactions (redness and pain), mild fatigue, and transient flu-like symptoms [8, 21]. Serious adverse events in controlled trials are rare, with no consistent organ-toxicity signal [21].

Research gaps

The evidence base relies heavily on systematic reviews, meta-analyses, and literature reviews rather than uniformly high-quality, large-scale primary RCT data [1, 7, 12, 14, 15, 17, 19, 22]. For COVID-19, authors explicitly note that further RCTs are required to verify findings [14]. Tα1 is not approved in the US, and the FDA notes there is no USP drug substance monograph for it [3, 13, 21]. Additionally, some regulatory and safety information is corroborated by commercial health websites, which are considered weaker evidence than peer-reviewed or regulatory sources [3, 8, 13, 21].

Editorial, sourced from primary literature - not medical advice.

Related peptides

Sources

← Back to peptides

Common use from studies